Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 2Liver Neoplasms 2Carcinoma 2

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × seocalcitol × Clear all
NCT00051532 2025-02-25

Seocalcitol Versus Placebo in Advanced Hepatocellular Carcinoma

LEO Pharma

Phase NA Terminated
700 enrolled
Gastrointestinal

Carcinoma, Liver Neoplasms, Neoplasms

NCT00051545 2025-02-25

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

LEO Pharma

Phase 3 Terminated
608 enrolled
Gastrointestinal

Carcinoma, Liver Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡